Home - Sana Biotechnology
Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.
Sana Biotechnology, Inc. (SANA) - Yahoo Finance
Find the latest Sana Biotechnology, Inc. (SANA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Sana Biotechnology Announces Positive Clinical Results from …
Jan 7, 2025 · First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression.
Sana Biotechnology Inc. - MarketWatch
4 days ago · Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing...
Our Science - Sana Biotechnology
We are developing platforms that can repair and control genes in cells or replace any cell in the body. We work with leading academic laboratories and industry partners on research and development related to our technologies.
Investor Relations | Sana Biotechnology, Inc
Dec 2, 2024 · Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients.
Our Pipeline - Sana Biotechnology
We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana. We are advancing a number of innovative drug candidates with the goal of disrupting the possible for patients across a diverse set of diseases.
Sana Biotechnology Announces FDA Clearance of Investigational …
Nov 9, 2023 · Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients.
Sana Biotechnology Announces Positive Clinical Results from …
Jan 7, 2025 · Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes.
Sana strips back cancer, CNS programs while warning of layoffs
Nov 5, 2024 · Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a strategic refocus that sounds likely to include a side order...